Mumbai, India-based Qure.ai closed a Series D funding round that included an investment by the Merck Global Health Innovation Fund.
The funding will go towards developing foundation models for AI in imaging and expanding Qure.ai’s reach into the U.S. market, the company said. The amount of the investment was undisclosed.
Qure.ai’s products cleared by the U.S. Food and Drug Administration include its qXR-LN chest x-ray lung nodule detection algorithm; qSpot-TB for detecting tuberculosis; and qER-Suite, an AI-enabled head CT tool to expedite the detection, triage, and quantification of traumatic brain injuries and stroke.
